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SUMMARY  
Objective: To raise awareness of the existence of a rare type of malignant trophoblastic tumor and discuss the 
diagnostic challenges and management of this lesion in a low resource setting.  
Case report and intervention: A 35 -year -old G6P3 woman was referred to our facility on account of persistent 
vaginal bleeding due to a suspected incomplete miscarriage with a cervical mass. Her serum β-HCG was elevated 
(36,900 mIU/ml) and examination showed a bleeding cervical mass. An initial histopathological diagnosis of 
moderately differentiated squamous cell carcinoma was reviewed to epithelioid trophoblastic tumor resulting in an 
extra-fascial hysterectomy. A final histopathological diagnosis of hybrid Epithelioid Trophoblastic Tumor and 
Choriocarcinoma (ETT/CC) was made after external review and immunohistochemistry. She received subsequent 
chemotherapy.  
Conclusion: Epithelioid trophoblastic tumor and its hybrids are difficult to diagnose. They may be diagnosed as 
moderately differentiated squamous cell carcinoma especially in low resource settings where cervical squamous cell 
carcinoma is relatively more common. A high index of suspicion, a serum β HCG test and close collaboration 
between clinicians and pathologists can help make the diagnosis.  
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INTRODUCTION 
Gestational trophoblastic diseases (GTD) are 
characterized by abnormal proliferation of placental 
trophoblasts and include benign and malignant lesions.1 
The malignant lesions are often referred to as 
Gestational Trophoblastic Tumours/Neoplasms (GTN). 
Epithelioid trophoblastic tumor is a rare neoplasm and 
represents the most recent addition to the gestational 
trophoblastic tumor category.2 ETT was first 
characterized in 1998 as a rare form of trophoblastic 
disease composed of intermediate trophoblasts, cells 
with features that made it distinct from placental-site 
trophoblastic tumor (PSTT) and choriocarcinoma (CC).3 
ETT is easily confused histopathologically with 
squamous cell carcinoma because of its frequent 
involvement of the lower uterine segment or 
endocervix, its epithelioid histologic appearance, and 
expression of p63 and cytokeratins.3  
 
Since its characterization as an entity, only up to one 
hundred (100) cases have been reported in the literature 
worldwide with 2 in South Africa.1, 2, 4 Hybrids of the 
entities that make up GTN exist, the commonest being a 
combination of ETT and CC and CC and PSTT.5,6 
Though there are many reports suggesting that 
gestational trophoblastic GTDs including GTNs are 
more common in Africa, with the exception of the two 
(2) ETTs reported in South Africa, we are unaware of 
any other cases of ETT or its hybrids reported in Sub-
Saharan Africa.7,-11 Suggestive clinical signs and 
symptoms such as bleeding per vaginam, elevated β-
Human Chorionic Gonadotropin (β-HCG) and 
suggestive radiological findings combined with 
thorough histopathological examination are required in 
the diagnosis, management and follow up of patients 
with rare GTNs and ensure a favorable outcome.12 
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CASE REPORT 
A 35 -year -old Gravida 6, Para 3 (2 Alive, 1 Dead) 
woman presented to a peripheral hospital with an eight 
(8) week history of spontaneous vaginal bleeding with 
lower abdominal pain. She was referred to our facility 
because of persistent vaginal bleeding after three (3) 
manual vacuum evacuations for what was thought to be 
an incomplete miscarriage and a cervical mass thought 
to be a leiomyoma. There was no histopathological 
examination of the evacuation specimens. On arrival at 
our facility, she could not remember her last menstrual 
period and her past obstetric history was unremarkable 
with no history of gestational trophoblastic disease. Her 
first and second pregnancies resulted in planned vaginal 
deliveries at term with no complications. Her third 
pregnancy ended as a second trimester loss at six (6) 
months. Her fourth and fifth pregnancies were lost in 
the first trimester. Her most recent pregnancy event was 
a spontaneous abortion, three months prior to this 
presentation. Physical examination showed a stable but 
pale woman with a pelvic mass, about fourteen (14) 
weeks size, mildly tender and slightly mobile but one 
could not go below the mass. There was no obvious 
superficial pelvic lymphadenopathy on palpation. 
Vaginal speculum exam showed a hemorrhagic cervical 
mass that bled on contact. Urine pregnancy test was 
positive and initial serum β-HCG was elevated, 36,900 
mIU/ml (5-270,000 mIU/ml). A pelvic ultrasound scan 
showed an empty uterus measuring 10.76x 6.02x 
8.45cm with a heterogeneous well-defined lesion in the 
cervical region measuring 6.34x6.21x6.94cm. The 
endometrium and adnexa were normal. A cervical 
curettage was done.  
 
Histopathologically, the first cervical curettage 
specimen was signed out as suggestive of a moderately 
differentiated squamous cell carcinoma. A second 
curettage specimen was requested and submitted 
because the first sample had only few viable areas based 
on which the initial diagnosis of moderately 
differentiated squamous cell carcinoma was made. This 
was then reviewed together with the first biopsy and in 
the context of the elevated β HCG, a diagnosis of 
Epithelioid Trophoblastic Tumor (ETT) was made. The 
patient then had an extra fascial total abdominal 
hysterectomy with conservation of both ovaries. The 
excised specimen showed a hemorrhagic 8x6cm mass 
confined to the cervix with histomorphology of ETT 
(Figure 1). The specimen was sampled per protocol and 
the hematoxylin and eosin stained sections reviewed 
with the initial biopsies. A diagnosis of ETT was made 
with a note to seek external consultation and carry out 
immunohistochemistry.  
External consultation with immunohistochemistry 
(Figure 2) concluded this was a hybrid Epithelioid 

























Figure 1 Showing gross and microscopic appearances 
of the tumor in the cervix. A (Gross location of tumor in 
the cervix) B, C, D (H&E: epithelioid islands with 



















Figure 2 showing immunohistochemical panel.   
 
Fifteen (15) days postoperatively, the patient’s serum β 
HCG dropped to 290.2 mIU/ml and then to 12 mIU/ml 
without chemotherapy.  
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After being lost to follow up for 4months without 
chemotherapy, the β HCG rose to 61.2 mIU/ml at which 
point chemotherapy with IV methotrexate was started 
resulting in a drop to 36.94 mIU/ml after a second cycle. 
There was however a rise in the β HCG to 59.24mIU/ml 
after the third cycle of chemotherapy requiring referral 
to the oncologist.  
 
DISCUSSION 
Our patient was in her reproductive years. Clinically, it 
is reported that ETT and hybrid ETTs primarily occur in 
reproductive-age women, though cases have been 
reported in postmenopausal women.3,5,6 ETT-like 
gestational CC occurs following a prior gestation with 
time from gestation to presentation reported to range 
from 1 year to as long as 18 years.3 The antecedent 
gestational events are reported to vary, including full 
term deliveries, spontaneous abortions and molar 
gestations with an average interval between the 
antecedent gestation and the development of the tumor 
reported as 6.2 years in one study.2 Hybrid GTNs 
similarly arise after pregnancy events and 
approximately one third of ETTs arise following a 
spontaneous abortion or hydatidiform mole, and 
majority after a full-term pregnancy.3,6 The index 
patient had three spontaneous abortions in the past 
following two previous term deliveries. The interval 
between the last spontaneous abortion, and her recent 
presentation to the hospital was 3 months. With no 
histopathological examination of previous curettage 
specimens, we are unable to classify the antecedent 
lesions histopathologically. It underscores the need to 
examine all such specimens in a histopathology 
laboratory. The most common presenting symptom of 
ETT and hybrid GTNs is reported as vaginal bleeding 
which was present in this patient. Together with a 
positive pregnancy test due to elevated serum β-human 
chorionic gonadotropin, this informed the initial 
diagnosis of spontaneous abortion at the peripheral 
facility. ‘Low’ elevations in serum β-human chorionic 
gonadotropin levels are reported for pure ETTs with 
levels generally not exceeding 2500 mIU/mL, unlike 
choriocarcinoma.3 Our patient’s initial serum β-HCG 
was 36,900 mIU/ml, higher than values reported for 
ETT though in keeping with the final diagnosis of 
hybrid ETT / Choriocarcinoma.3 Serum β-HCG is 
pivotal in the diagnosis of GTNs.  In low resource 
settings, a simple serum β-HCG test in women bleeding 
per vaginam will alert clinicians to the presence of 
GTNs.  
 
An ultrasound suggested a well-defined cervical lesion 
but did not seem to play a significant role in the 
subsequent diagnosis.  
The cervical leiomyoma was however not further 
investigated to be sure the diagnosis was correct. Lack 
of proper attention to the “cervical leiomyoma” led to 
delayed diagnosis and could have led to more serious 
consequences. It has however been reported that 
ultrasound in combination with Doppler are useful tools 
for diagnosing invasive GTNs, assessing treatment 
response, and detecting local recurrence. MRI is 
invaluable to assess extra uterine disease spread and 
complications. Chest radiograph, brain MRI, and body 
CT are primarily used to rule out metastatic disease.12 
The ultrasound findings and the initial diagnosis of ETT 
however informed the decision to do an extra-fascial 
total abdominal hysterectomy.  
 
The initial diagnosis of moderately differentiated 
squamous cell carcinoma following curettage is in line 
with reports that the gross morphology (cervical 
location), histo-morphology (pattern of invasion, 
necrosis and keratinoid debris) and cytological 
(epithelioid appearance) features of ETT mimic 
squamous cell carcinoma. 2, 3 One of such studies 
reported that, histopathologically, the most challenging 
differential diagnosis is to separate ETT from an 
invasive squamous cell carcinoma, particularly when it 
arises in the cervix or lower uterine segment as in this 
patient.2 In this patient the diagnosis was reviewed to 
ETT after additional tissue was submitted and the serum 
β-HCG level was brought to the attention of the 
reporting pathologist. This further emphasizes the 
importance of close collaboration between the 
pathologist and gynecologist in the management of 
GTNs.  
 
The initial drop in serum β-HCG following surgery and 
later resistance to routine chemotherapy with 
methotrexate are both in line with the predominant ETT 
composition of this patient’s tumor. ETTs are treated 
conventionally with hysterectomy. The later rise in 
serum β-HCG following surgery and prior to initiation 
of chemotherapy with methotrexate are in keeping with 
the component of choriocarcinoma and underscore the 
need to properly diagnose hybrid lesions since 
conventional treatment options for pure forms of GTNs 
will not suffice for hybrid GTNs. The later rise in serum 
β-HCG even after methotrexate therapy may be due the 
documented resistance of ETTs to conventional 
chemotherapy and the documented resistance of some 
high grade GTNs to methotrexate therapy.6 
 
CONCLUSION 
Epithelioid trophoblastic tumour and its hybrids are 
difficult to diagnose. They may be diagnosed as 
moderately differentiated squamous cell carcinoma 
especially in low resource settings where cervical 
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squamous cell carcinoma is relatively more common. A 
high index of suspicion, a serum β HCG test, relevant 
immunohistochemistry and close collaboration between 
clinicians and pathologists can help make the diagnosis.  
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